



# THE JOURNAL OF CLINICAL PSYCHIATRY

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

## Supplementary Material

**Article Title:** Determinants of Antipsychotic Response in Schizophrenia: Implications for Practice and Future Clinical Trials

**Author(s):** Jonathan Rabinowitz, PhD; Nomi Werbeloff, PhD; Ivo Caers, PhD; Francine S. Mandel, PhD; Virginia Stauffer, PharmD; François Ménard, MD; Bruce J. Kinon, MD; and Shitij Kapur, MBBS, PhD

**DOI Number:** 10.4088/JCP.13m08853

### List of Supplementary Material for the article

1. [eTable 1](#)

### Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary eTable 1.

Placebo controlled trials included in NEWMEDS

Name/Publication /Registration number	Treatment (active treatment, placebo sample sizes)	Regions	Fixed dose study
Repository			
Janssen			
RIS-INT-3 <sup>1, 2</sup> NCT00249132	Risperidone + Haloperidol: n=435 Placebo: n=88	North America	yes
RIS-USA-72 <sup>3</sup>	Risperidone: n=162 Placebo: n=83	North America	yes
RIS-USA-121 <sup>4</sup> NCT00253136	Risperidone: n=332 Placebo: n=107	North America	yes
RIS-USA-9001 <sup>5</sup>	Risperidone + Haloperidol: n=106 Placebo: n=54	North America	no
Ris-SCP-402 <sup>6</sup> NCT00061802	Risperidone + Quetiapine: n=309 Placebo: n=73	North America, Eastern Europe & Asia	no
R076477-SCH-301 <sup>7</sup> NCT00086320	Paliperidone: n=104 Placebo: n=102	North America, Eastern Europe, Middle East & Asia	no
R076477-SCH-302 <sup>8</sup> EUCTR2004-000326-70-CZ	Paliperidone: n=76 Placebo: n=38	Europe & South Africa	no
R076477-SCH-303 <sup>9</sup> NCT00078039	Paliperidone + Olanzapine: n=503 Placebo: n=126	Europe & Asia	yes
R076477-SCH-304 NCT00077714 <sup>10</sup>	Paliperidone + Olanzapine: n=503 Placebo: n=126	North America	yes
R076477-SCH-305 <sup>11</sup> NCT00668837	Paliperidone + Olanzapine: n=491 Placebo: n=123	North America, South America, Europe, Middle East & Asia	yes
R076477-SCH-3015 <sup>12</sup> NCT00334126	Paliperidone + Quetiapine: n=319 Placebo: n=80	North America, Eastern Europe, & Asia	no
Pfizer			
128-104	Ziprasidone: n=150 Placebo: n=50	North America	yes
128-106 <sup>13</sup>	Ziprasidone: n=91 Placebo: n=48	North America	yes
128-114 <sup>14</sup>	Ziprasidone: n=207 Placebo: n=91	North America	yes
128-115	Ziprasidone + Haloperidol: n=336 Placebo: n=83	North America	yes
128-303 <sup>15</sup>	Ziprasidone: n=219 Placebo: n=75	Eastern Europe	Yes
128-307	Ziprasidone: n=126 Placebo: n=64	Eastern Europe	Yes
Lundbeck			
M91-645	Sertindole: n=27 Placebo: n=11	North America	No
M92-762	Sertindole, n=157	North America	Yes

Name/Publication /Registration number	Treatment (active treatment, placebo sample sizes)	Regions	Fixed dose study
	Placebo: n=48		
M93-098	Sertindole + Haloperidol: n=346 Placebo: n=116	North America	Yes
M93-113 <sup>16</sup>	Sertindole + Haloperidol: n=424 Placebo: n=73	North America	Yes
M92-817	Sertindole + Haloperidol: n=114 Placebo: n=42	North America	Yes
Astra Zeneca			
5077IL/0006	Seroquel: n=53 Placebo: n=53	North America	No
5077IL/0013 <sup>17</sup>	Seroquel + Haloperidol: n=240 Placebo: n=39	North America	Yes
5077US/0001; 204,636/0008 <sup>18</sup>	Seroquel: n=186 Placebo: n=94	North America & Europe	No
D1444C00133 <sup>19</sup> NCT00085891	Seroquel: n=447 Placebo: n=117	North America	Yes
Lilly			
F1D-MC-HGAD <sup>20</sup>	Olanzapine + Haloperidol: n=267 Placebo: n=68	North America	No
F1D-MC-HGAP <sup>21</sup>	Olanzapine: n=101 Placebo: n=50	North America	Yes
Yes	North America & Eastern Europe	Olanzapine: n=305 Placebo: n=98	F1D-MC-HGJZ <sup>22</sup> NCT00088478
Integrated data base for validation			
Yes	Eastern Europe & Other	Bifeprunox: n=331 Placebo: n=166	LU10214
Yes	Eastern Europe & North America	Bifeprunox+Haloperidol: n=161 Placebo; n=53	S154.2.002
Yes	North America	Bifeprunox & Risperidone: n=408 Placebo, n=105	S154.2.010 <sup>23</sup>
Yes	North America & Other	Bifeprunox+Olanzapine: n=408 Placebo: n=129	S154.3.003
Yes	North America	Bifeprunox+ Risperidone: n=391 Placebo: n=127	S154.3.001

#### References

1. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. *J Clin Psychopharmacol*. Feb 1993;13(1):25-40.
2. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. *Am J Psychiatry*. Jun 1994;151(6):825-835.
3. Gutierrez R, Potkin SG. Efficacy and safety of once-daily dosing with risperidone in pts with schizophrenia. *35th Annual mtg of the Am. college of Neuropsychopharmacology*. San Juan, Puerto Rico 1996:259.
4. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. *Am J Psychiatry*. Jun 2003;160(6):1125-1132.
5. Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia. *Psychopharmacol Bull*. 1992;28(2):213-218.

6. Potkin SG, Gharabawi GM, Greenspan AJ, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. *Schizophr Res*. Jul 2006;85(1-3):254-265.
7. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. *J Clin Psychopharmacol*. Feb 2007;27(1):6-14.
8. Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. *Am J Geriatr Psychiatry*. Jan 2008;16(1):31-43.
9. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. *Schizophr Res*. Feb 2007;90(1-3):147-161.
10. Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. *Biol Psychiatry*. Dec 15 2007;62(12):1363-1370.
11. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. *Schizophr Res*. Jul 2007;93(1-3):117-130.
12. Canuso CM, Dirks B, Carothers J, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. *Am J Psychiatry*. Jun 2009;166(6):691-701.
13. Keck P, Jr., Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. *Psychopharmacology (Berl)*. Nov 1998;140(2):173-184.
14. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. *Neuropsychopharmacology*. May 1999;20(5):491-505.
15. Allison DB, Loebel AD, Lombardo I, Romano SJ, Siu CO. Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: effect modification or regression to the mean? *Psychiatry Res*. 2009;170(2-3):172-176.
16. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. *Am J Psychiatry*. Jun 1997;154(6):782-791.
17. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. *Biol Psychiatry*. Aug 15 1997;42(4):233-246.
18. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. *Arch Gen Psychiatry*. Jun 1997;54(6):549-557.
19. Cutler AJ, Tran-Johnson T, Kalali A, Astrom M, Brecher M, Meulien D. A failed 6-week, randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned. *Psychopharmacol Bull*. 2010;43(4):37-69.
20. Beasley CM, Jr., Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. *Neuropsychopharmacology*. Feb 1996;14(2):111-123.
21. Beasley CM, Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. *Psychopharmacology (Berl)*. Mar 1996;124(1-2):159-167.
22. Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. *J Clin Psychiatry*. May 2008;69(5):790-799.
23. Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. *Psychopharmacology (Berl)*. Oct 2008;200(3):317-331.